We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Read MoreHide Full Article
Key Takeaways
ANIP beat Q2 earnings and revenue estimates, but Cortrophin sales missed expectations.
ANIP cut 2026 Cortrophin guidance to $520-$540 million, while keeping its broader outlook intact.
Cortrophin needs about $338 million in second-half sales to reach the $530 million guidance midpoint.
ANI Pharmaceuticals, Inc. (ANIP - Free Report) topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix.
ANI kept its broader 2026 outlook intact after lowering Cortrophin guidance. The revised setup therefore puts more pressure on second-half execution, especially as the gout-focused sales expansion moves from hiring to patient-case generation.
ANIP's Q2 Beat Comes With a Cortrophin Miss
Second-quarter adjusted earnings of $2.21 per share beat the Zacks Consensus Estimate of $2.01. Revenues rose 26% year over year to $266 million and also exceeded the consensus estimate of $262.7 million.
Cortrophin revenues increased 43.5% to $117.1 million, but missed the $120.4 million consensus estimate. Rare Disease revenues of $135.8 million also fell short of the $141 million consensus mark, leaving a mixed read on ANIP's main growth engine.
ANI Cuts the 2026 Cortrophin Range
ANI lowered its 2026 Cortrophin revenue outlook to $520-$540 million from $540-$575 million. Even at the revised range, management expects 50-55% growth from 2025, showing that the product remains central to the company's expansion plan.
The company maintained total revenue guidance of $1.08-$1.14 billion, adjusted EBITDA guidance of $285-$300 million and adjusted earnings guidance of $9.19-$9.69 per share. Holding those targets steady leaves less room for another Cortrophin shortfall.
Cortrophin generated $192.2 million in the first half of 2026. Reaching the $530 million midpoint of full-year guidance would require roughly $338 million in the second half, or about 64% of the annual total.
Management expects third-quarter Cortrophin revenues of $143-$153 million, followed by further sequential growth in the fourth quarter. That implies a clear step-up from first-half levels and makes the pace of the back-half ramp a key operating test.
ANI's Gout Sales Force Must Translate Into Cases
ANI expanded its Rare Disease sales force by 50% to about 180 representatives, with the gout-focused organization fully operational by the end of June. By the end of July, more than 95% of new representatives had generated multiple patient cases.
The company estimates about 285,000 addressable patients with acute gouty arthritis flares. That creates substantial penetration room, but the near-term issue is conversion. More than one-third of prescribers had initiated at least two cases by the end of July, an early sign the larger field force is gaining traction.
ANIP Has Backup From Iluvien and Generics
Iluvien's 2026 revenue guidance remains $78-$83 million, while Generics generated $204.5 million in the first half, up 8% year over year. ANI also launched 12 generic products through June and expects at least 15 launches for the full year.
The retina business still faces established competition. AbbVie Inc. (ABBV - Free Report) competes through Ozurdex in diabetic macular edema and non-infectious uveitis. Regeneron Pharmaceuticals, Inc. (REGN - Free Report) competes through Eylea and Eylea HD in diabetic macular edema. That makes execution in Iluvien important as ANI leans on multiple businesses to support its companywide outlook.
ANIP's Factor Scores Clash With Near-Term Caution
The main question is whether Cortrophin can deliver the expected second-half acceleration without forcing another reset to guidance. The unchanged broader outlook gives ANI several ways to absorb variability, but Cortrophin's rising revenue concentration increases the importance of execution.
ANIP currently has a Zacks Rank #4 (Sell). At the same time, it has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those favorable Style Scores point to attractive value, growth and momentum characteristics, but they are designed to complement the Zacks Rank rather than override it. The #4 Rank keeps the near-term signal cautious as investors watch whether the expected Cortrophin ramp materializes.
View the Zacks #1 Rank List
Image: Bigstock
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Key Takeaways
ANI Pharmaceuticals, Inc. (ANIP - Free Report) topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix.
ANI kept its broader 2026 outlook intact after lowering Cortrophin guidance. The revised setup therefore puts more pressure on second-half execution, especially as the gout-focused sales expansion moves from hiring to patient-case generation.
ANIP's Q2 Beat Comes With a Cortrophin Miss
Second-quarter adjusted earnings of $2.21 per share beat the Zacks Consensus Estimate of $2.01. Revenues rose 26% year over year to $266 million and also exceeded the consensus estimate of $262.7 million.
Cortrophin revenues increased 43.5% to $117.1 million, but missed the $120.4 million consensus estimate. Rare Disease revenues of $135.8 million also fell short of the $141 million consensus mark, leaving a mixed read on ANIP's main growth engine.
ANI Cuts the 2026 Cortrophin Range
ANI lowered its 2026 Cortrophin revenue outlook to $520-$540 million from $540-$575 million. Even at the revised range, management expects 50-55% growth from 2025, showing that the product remains central to the company's expansion plan.
The company maintained total revenue guidance of $1.08-$1.14 billion, adjusted EBITDA guidance of $285-$300 million and adjusted earnings guidance of $9.19-$9.69 per share. Holding those targets steady leaves less room for another Cortrophin shortfall.
ANI Pharmaceuticals, Inc. Price and Consensus
ANI Pharmaceuticals, Inc. price-consensus-chart | ANI Pharmaceuticals, Inc. Quote
ANIP's Second-Half Math Gets More Demanding
Cortrophin generated $192.2 million in the first half of 2026. Reaching the $530 million midpoint of full-year guidance would require roughly $338 million in the second half, or about 64% of the annual total.
Management expects third-quarter Cortrophin revenues of $143-$153 million, followed by further sequential growth in the fourth quarter. That implies a clear step-up from first-half levels and makes the pace of the back-half ramp a key operating test.
ANI's Gout Sales Force Must Translate Into Cases
ANI expanded its Rare Disease sales force by 50% to about 180 representatives, with the gout-focused organization fully operational by the end of June. By the end of July, more than 95% of new representatives had generated multiple patient cases.
The company estimates about 285,000 addressable patients with acute gouty arthritis flares. That creates substantial penetration room, but the near-term issue is conversion. More than one-third of prescribers had initiated at least two cases by the end of July, an early sign the larger field force is gaining traction.
ANIP Has Backup From Iluvien and Generics
Iluvien's 2026 revenue guidance remains $78-$83 million, while Generics generated $204.5 million in the first half, up 8% year over year. ANI also launched 12 generic products through June and expects at least 15 launches for the full year.
The retina business still faces established competition. AbbVie Inc. (ABBV - Free Report) competes through Ozurdex in diabetic macular edema and non-infectious uveitis. Regeneron Pharmaceuticals, Inc. (REGN - Free Report) competes through Eylea and Eylea HD in diabetic macular edema. That makes execution in Iluvien important as ANI leans on multiple businesses to support its companywide outlook.
ANIP's Factor Scores Clash With Near-Term Caution
The main question is whether Cortrophin can deliver the expected second-half acceleration without forcing another reset to guidance. The unchanged broader outlook gives ANI several ways to absorb variability, but Cortrophin's rising revenue concentration increases the importance of execution.
ANIP currently has a Zacks Rank #4 (Sell). At the same time, it has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those favorable Style Scores point to attractive value, growth and momentum characteristics, but they are designed to complement the Zacks Rank rather than override it. The #4 Rank keeps the near-term signal cautious as investors watch whether the expected Cortrophin ramp materializes.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.